Supplements · Gut & Microbiome
probiotics treats irritable bowel syndrome
Part of: 🧪 Probiotics
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Multistrain probiotics reduce IBS symptom severity (less clear for QoL).
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sommermeyer H et al] # corrected 2026-08-17 from PubMed; was [et al. 2024 · Nutrients | RCT | supports | moderate | Multicenter RCT (9-strain synbiotic, n=202): IBS-SSS/IBS-GIS improved; 70% adequate relief vs placebo. |
| Ghoshal UC et al 2026 · study_type: RCT | RCT | supports | high | RCT n=200 non-constipated IBS, 84d: LA-5+BB-12 blend improved IBS-GIS response (19.3% vs 8.9% by day28, p=0.048), IBS-SSS and IBS-QoL vs placebo through day 84 (p<0.001); no fecal microbiota difference. |
| Maslennikov R et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | SR/MA single-strain RPCTs, 32 studies/10 strains: 5 strains (B. longum 35624, L. rhamnosus GG, L. plantarum 299v, S. cerevisiae I-3856, B. coagulans IS2) effective; E. coli Nissle, L. gasseri BNR17, L. casei Shirota NOT. |
| Piccirillo M et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | Pediatric SR/MA, 6 RCTs n=604 (3 pooled): probiotics reduced abdominal pain (SMD -0.95 [-1.63,-0.27]) and normalized stool consistency (OR 2.17 [1.18,4]) vs placebo. |
| skrzydlo-2021 2021 | RCT | supports | moderate | RCT (multistrain, IBS-D): significant symptom-severity/adequate-relief improvement vs placebo; well tolerated. |
| Tang ASP et al 2026 · study_type: meta-analysis | meta-analysis | mixed | moderate | 40 RCTs: probiotics improved IBS-SSS (MD -33.42 [-55.96,-10.88], p<0.01) but NOT IBS-QOL (MD 1.79 [-3.00,6.57], p=0.46); GRADE=low certainty, inconsistency-driven; TSA underpowered. |
| Rezazadegan M et al 2026 · study_type: RCT | RCT | mixed | moderate | 3-arm RCT n=84: zinc+probiotic improved IBS severity vs placebo (-195.71 vs -73.21, p=0.003) but zinc-alone did as well/better; probiotic add-on worsened mood scores vs zinc alone. |
| Anwar H, et al. 2025 · Eur J Gastroenterol Hepatol | meta-analysis | supports | low | IBS-SSS MD −43.66 (−65.89,−21.44); QoL & abdominal-pain subscores NS; I²≈99%. |
| Ballena-Caicedo J et al 2026 · study_type: meta-analysis | meta-analysis | supports | low | Umbrella review, 27 SRs (5-82 RCTs each): symptom persistence RR~0.78-0.79 (NNT 4-7), abdominal pain SMD -0.31 to -0.94 w/ substantial heterogeneity; 66.7% SRs AMSTAR-2 critically-low; only 1% outcomes high-certainty. |
| Almalki AS et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | SR/MA, 16 RCTs n=2823: probiotics reduced intestinal discomfort (MD -93.9 [-133.1,-54.7], p<0.00001) and improved global symptoms (OR 1.71 [1.26,2.33], p=0.0006) vs placebo; well tolerated. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.